Confluent raises funds for adhesion barrier trial:
This article was originally published in Clinica
Biosurgery company Confluent Surgical, which develops products based on in situ polymerised hydrogel polymers and associated delivery systems, has raised $20m in a venture funding round. The Waltham, Massachusetts-based company's products are designed for post-surgical adhesion prevention and surgical sealing applications. The company will use the funds to support the completion of US trials into the SprayGel adhesion barrier, as well as extending the company's portfolio into surgical sealants for neuro, spine and cardiovascular surgery.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.